On November 13, 2024 Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP020241113_Laevoroc LOI_Final") ("Helix" or the "Company), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immuno-oncology, based on its proprietary technological CEACAM6 platform, DOS47, reported that the Company has entered into a non-binding letter of intent (LOI) to acquire a 100% interest in the oncology assets of Laevoroc Chemotherapy AG and Laevoroc Immunology AG, both privately-held, Swiss oncology companies (Press release, Helix BioPharma, NOV 13, 2024, View Source [SID1234648246]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HELIX BIOPHARMA CORP. ENTERS INTO NON-BINDING LOI TO ACQUIRE LAEVOROC GROUP’S ONCOLOGY ASSETS